The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
We herein present an overview of the upcoming 5th edition of the World Health Organization
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid …
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Unprecedented advances in our understanding of the pathobiology, prognostication, and
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …
therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years …
The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee
Since the publication of the Revised European-American Classification of Lymphoid
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have …
[HTML][HTML] Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study
Purpose Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium
PURPOSE Brexucabtagene autoleucel (brexu-cel) is an autologous CD19-directed chimeric
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …
antigen receptor (CAR) T-cell therapy approved for relapsed/refractory mantle cell …
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1
rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non …
rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non …
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
P Jain, ML Wang - American journal of hematology, 2022 - Wiley Online Library
The field of mantle cell lymphoma (MCL) has witnessed remarkable progress due to
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
relentless advances in molecular pathogenesis, prognostication, and newer treatments …
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
S Yi, Y Yan, M Jin, S Bhattacharya… - The Journal of …, 2022 - Am Soc Clin Investig
Mantle cell lymphoma (MCL) is a phenotypically and genetically heterogeneous malignancy
in which the genetic alterations determining clinical indications are not fully understood …
in which the genetic alterations determining clinical indications are not fully understood …
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
R Agarwal, YC Chan, CS Tam, T Hunter… - Nature medicine, 2019 - nature.com
Ibrutinib plus venetoclax is a highly effective combination in mantle cell lymphoma.
However, strategies to enable the evaluation of therapeutic response are required. Our …
However, strategies to enable the evaluation of therapeutic response are required. Our …